AR039703A1 - Composiciones nasales - Google Patents

Composiciones nasales

Info

Publication number
AR039703A1
AR039703A1 ARP030102157A ARP030102157A AR039703A1 AR 039703 A1 AR039703 A1 AR 039703A1 AR P030102157 A ARP030102157 A AR P030102157A AR P030102157 A ARP030102157 A AR P030102157A AR 039703 A1 AR039703 A1 AR 039703A1
Authority
AR
Argentina
Prior art keywords
nasal
mucopolysaccharide
active substance
composition according
nasal compositions
Prior art date
Application number
ARP030102157A
Other languages
English (en)
Original Assignee
Novartis Consumer Health Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Consumer Health Sa filed Critical Novartis Consumer Health Sa
Publication of AR039703A1 publication Critical patent/AR039703A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Abstract

Composiciones farmacéuticas adecuadas para administración nasal. Las formulaciones nasales de la presente se caracterizan, entre otras cosas, por tener excelente propiedades humectantes, y por no requerir de un conservador. Reivindicación 1: Una composición farmacéutica nasal que comprende: a) cuando menos una sustancia activa adecuada para administración nasal; b) un mucopolisacárido; y c) propilenglicol. Reivindicación 3: Una composición de acuerdo con la reivindicación 1, en donde la sustancia activa (a) es xilometazolina o una sal nasalmente aceptable de la misma. Reivindicación 5: Una composición de acuerdo con cualquiera de las reivindicaciones 1 a 4, en donde el mucopolisacárido (b) es sulfato de condroitina.
ARP030102157A 2002-06-20 2003-06-18 Composiciones nasales AR039703A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02013693 2002-06-20

Publications (1)

Publication Number Publication Date
AR039703A1 true AR039703A1 (es) 2005-03-09

Family

ID=29797130

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102157A AR039703A1 (es) 2002-06-20 2003-06-18 Composiciones nasales

Country Status (12)

Country Link
US (1) US20050129622A1 (es)
EP (1) EP1517673A1 (es)
JP (1) JP2005533076A (es)
AR (1) AR039703A1 (es)
AU (1) AU2003278962B2 (es)
CA (1) CA2489528A1 (es)
NO (1) NO20050215L (es)
NZ (1) NZ537186A (es)
PL (1) PL373033A1 (es)
RU (1) RU2005101331A (es)
TW (1) TW200402307A (es)
WO (1) WO2004000272A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1507543A4 (en) * 2002-05-09 2006-07-26 Cambridgemed Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF WOOD WITH BLOOD PLASMA OR SERUM
JP2005075735A (ja) * 2003-08-28 2005-03-24 Rohto Pharmaceut Co Ltd オキシメタゾリン含有組成物
DE10356248A1 (de) * 2003-11-13 2005-06-23 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden
US7323184B2 (en) * 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
FR2901706A1 (fr) * 2006-06-01 2007-12-07 Persee Medica Soc Par Actions Compositions nasale et buccale pour lutter contre le ronflement
FR2901705A1 (fr) * 2006-06-01 2007-12-07 Persee Medica Soc Par Actions Composition pour lutter contre le ronflement se presentant sous la forme d'un spray nasal
DE102007006122A1 (de) * 2007-02-02 2008-08-07 Krewel Meuselbach Gmbh Cistusextrakte
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
WO2012119261A1 (en) * 2011-03-10 2012-09-13 Biocia Inc. Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
KR102350848B1 (ko) * 2013-09-11 2022-01-14 에이아이엠 타겟티드 테라피즈 인코포레이티드 고장성 항미생물 치료 조성물
EP3681474A1 (en) * 2017-09-11 2020-07-22 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for nasal administration of drugs to brain and for systemic effect

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945636A1 (de) * 1979-11-12 1981-05-21 Sandoz-Patent-GmbH, 7850 Lörrach Stabile loesungen von hydrierten ergotalkaloiden bzw. ihren salzen und heparin bzw. seinen salzen sowie verfahren zu deren herstellung
US4402949A (en) * 1979-11-12 1983-09-06 Sandoz Ltd. Stable solutions of hydrogenated ergotalkaloids
AU655919B2 (en) * 1990-02-22 1995-01-19 Macnaught Pty Limited Artificial tears
IT1273742B (it) * 1994-08-01 1997-07-09 Lifegroup Spa Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose
DE19549421C2 (de) * 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
JPH10231243A (ja) * 1997-02-20 1998-09-02 Sekisui Chem Co Ltd 粘膜炎症外用薬
WO1998048839A1 (en) * 1997-04-30 1998-11-05 Warner-Lambert Company Topical nasal antiinflammatory compositions
JPH1179994A (ja) * 1997-09-08 1999-03-23 Ikeda Mohandou:Kk 点鼻適用製剤
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
PL340606A1 (en) * 1997-10-22 2001-02-12 Jens Ponikau Methods of and materials for treating and preventing mucositis
EP1051155B1 (en) * 1998-01-30 2002-06-26 Novartis Consumer Health S.A. Nasal solutions
US20010053775A1 (en) * 1998-01-30 2001-12-20 Matthias Seidel Nasal solutions
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
PT1194145E (pt) * 1999-06-22 2003-06-30 Boehringer Ingelheim Int Solucao estavel de xilometazolina e de oximetazolina
JP2001072605A (ja) * 1999-09-03 2001-03-21 Lion Corp 経皮経粘膜吸収促進剤組成物
US20030086899A1 (en) * 2000-03-14 2003-05-08 Jafari Masoud R. Chondroitin sulfate containing viscoelastics for use in treating joints
CA2423354C (en) * 2000-09-20 2009-12-15 Lee Shahinian Jr. Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea

Also Published As

Publication number Publication date
CA2489528A1 (en) 2003-12-31
WO2004000272A1 (en) 2003-12-31
EP1517673A1 (en) 2005-03-30
NO20050215L (no) 2005-01-13
US20050129622A1 (en) 2005-06-16
PL373033A1 (en) 2005-08-08
AU2003278962C1 (en) 2004-01-06
AU2003278962A1 (en) 2004-01-06
RU2005101331A (ru) 2006-01-20
JP2005533076A (ja) 2005-11-04
NZ537186A (en) 2006-10-27
AU2003278962B2 (en) 2006-11-23
TW200402307A (en) 2004-02-16

Similar Documents

Publication Publication Date Title
AR039703A1 (es) Composiciones nasales
AR109263A2 (es) Composición que comprende moxidectina
ATE478841T1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
ATE464880T1 (de) Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
AR052853A1 (es) Composiciones orales que contienen compuestos antibacterianos de bifenol
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
MXPA05001061A (es) Composiciones farmaceuticas, acuosas de 2,6-diisopropilfenol.
CR20220675A (es) Análogos de nucleósido de 1´- ciano y usos de los mismos
AR109357A2 (es) Composición farmacéutica parenteral con tolerancia en el sitio de inyección
BRPI0408240A (pt) composto, utilização de um composto e composição farmacêutica
BRPI0412502A (pt) derivados de ariltiouréia substituìda úteis como inibidores de replicação viral
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
AR027360A1 (es) Composicion farmaceutica
GB2421241A (en) Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof
SE0102055D0 (sv) New Compounds
ATE528009T1 (de) Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
BR9912817A (pt) Composição terapêutica à base de isoflavonóides destinada a ser utilizada no tratamento dos tumores por agentes citotóxicos
BRPI0406734A (pt) Composição termiticida, e, método para controlar térmitas
BR0011845A (pt) Complexo farmacêutico
SV2001000093A (es) Formas polimorfas de un citrato de azobiciclo 2,2,2, octan-3-amina y sus composiciones farmaceuticas ref.pcl0216/82962/bb
BR0210063A (pt) Composição estável e uso da mesma
BR9807506A (pt) Derivados de amida e composições medicinais dos mesmos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal